Rituximab maintenance therapy in central nervous system lymphoma?
Murawski
Niels
N
Department of Internal Medicine, Saarland University Medical School, Homburg, Saarland, Germany.
Pfreundschuh
Michael
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D012189:Retrospective Studies; D000069283:Rituximab; D016879:Salvage Therapy; D000077204:Temozolomide
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D003606:Dacarbazine; D000077204:Temozolomide